Effectiveness evaluation of Tofacitinib plus Remdesivir in comparison with Remdesivir in the treatment of adult patients with severe COVID-19 A randomized double-blind placebo-included clinical trial

Rasht University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年4月26日

适应症

试验速览

暂无简介。

•All patients with severe Covid-19 admitted to the ICU of Razi Hospital in Rasht for period of March- June 2021
•Age greater than or equal to 18 years
•Patients admitted with the following criteria: fever (oral temperature greater than 37.2 ° C), dry cough, severe tiredness or dyspnea
•At least one of the following criteria : positive PCR OR lung involvement on chest X-ray / CT scan
•Absolute lymphocyte count greater than or equal to 200 per cubic millimeter
•Absolute neutrophil count greater than or equal to 1000 per milliliter Cubic meters
•Hemoglobin above 8 grams per deciliter

•Lack of informed consent
•Lack of patient cooperation
•Having pulmonary embolism or intravascular thrombosis
•Having another active infection
•Having diverticulitis and gastric ulcer
•Having tuberculosis or hepatitis B or active hepatitis C or HIV
•Any major drug interaction between routine patient's drugs with any of the study drugs
•Pregnancy and lactation
•Simultaneous presence in other research study

发起方

Rasht University of Medical Sciences